Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).
| dc.contributor.author | Soria, Jean-Charles | |
| dc.contributor.author | Felip, Enriqueta | |
| dc.contributor.author | Cobo, Manuel | |
| dc.contributor.author | Lu, Shun | |
| dc.contributor.author | Syrigos, Konstantinos N. | |
| dc.contributor.author | Lee, Ki Hyeong | |
| dc.contributor.author | Goker, Erdem | |
| dc.contributor.author | Georgoulias, Vassilis | |
| dc.contributor.author | Li, Wei | |
| dc.contributor.author | Isla, Dolores | |
| dc.contributor.author | Guclu, Salih Zeki | |
| dc.contributor.author | Morabito, Alessandro | |
| dc.contributor.author | Min, Young Joo | |
| dc.contributor.author | Ardizzoni, Andrea | |
| dc.contributor.author | Gadgeel, Shirish M. | |
| dc.contributor.author | Wang, Bushi | |
| dc.contributor.author | Chand, Vikram K. | |
| dc.contributor.author | Goss, Glenwood D. | |
| dc.date.accessioned | 2019-10-27T23:00:26Z | |
| dc.date.available | 2019-10-27T23:00:26Z | |
| dc.date.issued | 2015 | |
| dc.department | Ege Üniversitesi | en_US |
| dc.description | Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL | en_US |
| dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
| dc.identifier.issn | 0732-183X | |
| dc.identifier.issn | 1527-7755 | |
| dc.identifier.issue | 15 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11454/52000 | |
| dc.identifier.volume | 33 | en_US |
| dc.identifier.wos | WOS:000358036901715 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Amer Soc Clinical Oncology | en_US |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.title | Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). | en_US |
| dc.type | Conference Object | en_US |
